Blogs about: Genentech
Featured Blog
Phase III Avastin trial in Colon Cancer to continue
Genentech have announced that its ongoing Phase III study of Avastin (bevacizumab) in patients with early-stage colon cancer will continue as planned. … more →
Kinase News
Today's Top Pharma News 071009
— 1 comment
Steve Woodruff wrote 1 week ago: Roche-Genentech – the cuts begin – Anxiety rippled through Genentech this week as the Sw … more →
Post-Vacation Brain Dump: Deal Developments
— 1 comment
Jeremy G wrote 2 weeks ago: Some exciting deal news from the week: Neuromed, which licensed U.S. rights to its lead candidate E … more →
Why does Roche Drop PhRMA Membership?
Audrey Erbes wrote 2 weeks ago: Now come on…is Roche so naive to believe that industry folks will think Genentech is not Roche … more →
Facebook Taps Ex-Genentech Exec Ebersman As CFO
— 1 comment
Jennifer Martinez wrote 2 weeks ago: Facebook said today that former Genentech executive vice president and CFO David Ebersman will join … more →
Arbitration panel reaffirms Biogen Idec's contractual right under collaboration with Genentech
silico wrote 1 month ago: Biogen Idec has announced that an arbitration panel has issued its decision concerning the company … more →
Bayhill Therapeutics sign diabetes collaboration agreement with Genentech
silico wrote 1 month ago: Bayhill Therapeutics has announced that it has entered into an exclusive worldwide license agreement … more →
More women fall off the tracks
— 2 comments
Patricia Sellers wrote 1 month ago: The ouster of Bank of America’s (BAC) chief risk officer, Amy Brinkley, was inevitable, as I w … more →
US Federal anti-trust probe targets tech giants, sources say.
pdalbury wrote 1 month ago: [Washington Post - Cecilia Kang] The U.S. Justice Department has launched an investigation into whet … more →
Today's Top Three in Pharma 060409
Steve Woodruff wrote 1 month ago: OK, so it’s a “baker’s three” (8) today. Makes up for yesterday’s zer … more →
Tech companies under antitrust investigation
— 3 comments
josephlogan wrote 1 month ago: Some high-profile companies are being investigated for what appears to be a “gentlemen’ … more →
Keryx: Another beneficiary of the ASCO-effect
Michael Becker wrote 1 month ago: In my prior article, I highlighted the “ASCO-effect,” which relates to the fact that biotechnology c … more →
Victoria Hale, Ph.D.: A Visionary Making Affordable Drugs for Developing World
Vince Reardon wrote 1 month ago: After years of hard work and one challenging job after another, Victoria Hale had arrived. “I had at … more →
Genentech president jumps to a new life
Patricia Sellers wrote 2 months ago: Another Fortune Most Powerful Woman — a longtime member of our annual Power 50 list — is … more →
Susan Desmond-Hellmann Named UCSF Chancellor
Zen of Bass wrote 2 months ago: Susan Desmond-Hellmann, one of FORTUNE’s Most Powerful Women in Business, will become the fir … more →
Today's Top Three in Pharma 042309
Steve Woodruff wrote 2 months ago: FDA extends review of AstraZeneca/BMS experimental diabetes drug Onglyza. Teva blocked from launchin … more →
Today's Top Three in Pharma 041609
Steve Woodruff wrote 3 months ago: GSK and Pfizer join forces to create a new company focused on HIV. I really like the idea here … more →
"So Here Goes"--Genentech Under Roche Management
Audrey Erbes wrote 3 months ago: Will the company go up or down? Thats the question that employees, investors, by standers, admirers … more →
Raptiva News
diplomatsp wrote 3 months ago: Psoriasis patients will want to pay attention to the news about Raptiva. Genentech said it’s p … more →
Today's Top Three in Pharma 040909
Steve Woodruff wrote 3 months ago: Genentech pulls Raptiva from the U.S. market. Risk/benefit ratio got too dicey. AstraZeneca gets a l … more →
Have your say. Start a blog.
See our free features →
An 
Contraption
